longboardpharma.com (LBPH) - Long-Term Liabilities to Capital

Longboard Pharmaceuticals (LBPH) specializes in developing innovative treatments for pediatric seizures, leveraging unique patented technologies. This price chart reflects the launch of final-stage trials for the lead drug candidate, while the 0.01 metric captures the current trend. However, geopolitical instability and trade restrictions are significantly slowing down international drug registration and scientific collaboration.

For Longboard Pharmaceuticals (LBPH), whose primary catalysts are tied to Phase 3 clinical trials, the long-term debt-to-equity ratio determines the extent to which pipeline development depends on borrowed funds. This metric is calculated as the ratio of liabilities with a maturity of more than one year to total equity. By analyzing the long-term debt leverage ratio on GURU.Markets, an investor can track the dynamics of the debt load. This allows for an assessment of the risk of share dilution during secondary offerings. A low leverage level confirms the financial stability of the business.